Announced details
Regenerative medicine, treatment of refractory skin ulcers, platelets for transfusion, PRP therapy
Toho Holdings invested in AdipoSeeds and will support its research and development through the investment.
Headquartered within Keio University School of Medicine at 35 Shinanomachi, Shinjuku-ku, Tokyo. The representative director and president is Fuwa Junji (不破 淳二). Established on 7 July 2016. The company develops regenerative medicine products, including multifunctional platelets derived from adipose tissue, ASCL-PLC, and operates a business for PRP therapy. Capital: ¥110 million (as of June 2026). A venture spun out of Keio University School of Medicine.
Within Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo
The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | ASCL-PLC, Therapeutic agent for refractory skin ulcers, Platelets for transfusion, PRP therapy |
| Counterparty | AdipoSeeds Co., Ltd. |
| Counterparty overview | Headquartered within Keio University School of Medicine at 35 Shinanomachi, Shinjuku-ku, Tokyo. The representative director and president is Fuwa Junji (不破 淳二). Established on 7 July 2016. The company develops regenerative medicine products, including multifunctional platelets derived from adipose tissue, ASCL-PLC, and operates a business for PRP therapy. Capital: ¥110 million (as of June 2026). A venture spun out of Keio University School of Medicine. |
| Relationship with the Company | Toho Holdings invested in AdipoSeeds and will support its research and development through the investment. |
| Applicable area | Regenerative medicine, treatment of refractory skin ulcers, platelets for transfusion, PRP therapy |
| Location | Within Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo |
| Impact on Business Performance | The impact is currently immaterial. Over the medium to long term, the investment is expected to contribute to increasing the corporate value of the Toho Holdings Group. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To support AdipoSeeds' research and development and strengthen Toho Holdings' portfolio of regenerative medicine, cellular medicine and other products.